Our Halogen-Enriched Fragment Library comprises 708 brominated fragments that can explore binding sites for favorable halogen bond interactions to identify unique binding modes that are complementary to those obtained from classical fragment-based screening.
 

In recent years, structured RNAs have become tractable drug targets, enabling the discovery of selective modulators for riboswitches, long noncoding RNAs, G-quadruplexes, and RNA–protein complexes.
Breakthrough advances in library design, screening methodologies, and AI-based prioritization have expanded the scope of RNA-targeted drug discovery (Kovachka et al., Nat Rev Chem 2024; Lundquist et al., SLAS Discovery 2025; Morishita, ChemMedChem 2022; Momentum Bio, 2024).
Modern RNA-focused screening now combines:

• Affinity Selection–Mass Spectrometry (AS-MS) for label-free, solution-phase discovery,

• SPR/BLI for kinetic profiling and specificity ranking,

• AI-guided virtual enrichment to prioritize compounds with high “RNA-likeness” before experimental testing (Graff et al., Chem Sci 2020; Cao et al., Nat Mach Intell 2023).